Publications
775 results found
Russell AM, Doyle AM, Ross D, et al., 2015, PATIENT AND CARER CO-INVESTIGATORS: SHARED EXPERIENCES OF A RESEARCH STEERING GROUP FROM THE IDIOPATHIC PULMONARY FIBROSIS PATIENT REPORTED OUTCOME MEASURE (IPF-PROM) STUDY, Winter Meeting of the British-Thoracic-Society, Publisher: BMJ PUBLISHING GROUP, Pages: A76-A77, ISSN: 0040-6376
George PM, Richardson L, Renzoni EA, et al., 2015, EFFECT OF PIRFENIDONE ON GAS TRANSFER IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS, Winter Meeting of the British-Thoracic-Society, Publisher: BMJ PUBLISHING GROUP, Pages: A79-A79, ISSN: 0040-6376
Fisher M, Maher T, Hill C, et al., 2015, DISEASE PROGRESSION MODELLING IN IDIOPATHIC PULMONARY FIBROSIS: A PREDICTION OF TIME TO DISEASE PROGRESSION AND LIFE EXPECTANCY WITH PIRFENIDONE, Winter Meeting of the British-Thoracic-Society, Publisher: BMJ PUBLISHING GROUP, Pages: A61-A61, ISSN: 0040-6376
De Lauretis A, Ward S, Murray C, et al., 2015, ROLE OF NON ACID AND PROXIMAL REFLUX IN SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE, Winter Meeting of the British-Thoracic-Society, Publisher: BMJ PUBLISHING GROUP, Pages: A92-A92, ISSN: 0040-6376
Maher TM, 2015, Aerobic Glycolysis and the Warburg Effect An Unexplored Realm in the Search for Fibrosis Therapies?, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 192, Pages: 1407-1409, ISSN: 1073-449X
- Author Web Link
- Cite
- Citations: 31
Fletcher SV, Jones MG, Renzoni E, et al., 2015, NINTEDANIB FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS - INITIAL CLINICAL EXPERIENCE IN A UK COHORT, Winter Meeting of the British-Thoracic-Society, Publisher: BMJ PUBLISHING GROUP, Pages: A78-A78, ISSN: 0040-6376
- Author Web Link
- Cite
- Citations: 4
Maher T, Cottin V, Azuma A, et al., 2015, PIRFENIDONE POST-AUTHORISATION SAFETY REGISTRY (PASSPORT) - UPDATE AND CONCOMITANT USE OF N-ACETYLCYSTEINE AND/OR CORTICOSTEROIDS, Winter Meeting of the British-Thoracic-Society, Publisher: BMJ PUBLISHING GROUP, Pages: A79-A80, ISSN: 0040-6376
Saunders P, Stock CJ, Molyneaux PL, et al., 2015, MUC5B GENOTYPE DOES NOT INFLUENCE COUGH SEVERITY IN IPF, Winter Meeting of the British-Thoracic-Society, Publisher: BMJ PUBLISHING GROUP, Pages: A29-A29, ISSN: 0040-6376
Kokosi M, Saunders P, Karagiannis K, et al., 2015, RITUXIMAB AS RESCUE THERAPY IN ADVANCED PROGRESSIVE SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE, Winter Meeting of the British-Thoracic-Society, Publisher: BMJ PUBLISHING GROUP, Pages: A92-A92, ISSN: 0040-6376
Maher TM, Whyte MK, Hoyles RK, et al., 2015, Development of a consensus statement for the definition, diagnosis, and treatment of acute exacerbations of idiopathic pulmonary fibrosis using the Delphi technique, Advances in Therapy, Vol: 32, Pages: 929-943, ISSN: 1865-8652
INTRODUCTION: There is a lack of agreed and established guidelines for the treatment of acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF). This reflects, in part, the limited evidence-base underpinning the management of AE-IPF. In the absence of high-quality evidence, the aim of this research was to develop a clinician-led consensus statement for the definition, diagnosis and treatment of AE-IPF. METHODS: A literature review was conducted to obtain published material on the definition and treatment of AE-IPF. The results of this review were circulated to an online panel of clinicians for review. Statements were then shared with ten expert respiratory clinicians who regularly treat patients with IPF. A Delphi technique was then used to develop a consensus statement for the definition, diagnosis and treatment of AE-IPF. During the first round of review, clinicians rated the clarity of each statement, the extent to which the statement should be included and provided comments. In two subsequent rounds of review, clinicians were provided with the group median inclusion rating for each statement, and any revised wording of statements to aid clarity. Clinicians were asked to repeat the clarity and inclusion ratings for the revised statements. RESULTS: The literature review, online panel discussion, and face-to-face meeting generated 65 statements covering the definition, diagnosis, and management of AE-IPF. Following three rounds of blind review, 90% of clinicians agreed 39 final statements. These final statements included a definition of AE-IPF, approach to diagnosis, and treatment options, specifically: supportive measures, use of anti-microbials, immunosuppressants, anti-coagulants, anti-fibrotic therapy, escalation, transplant management, and long-term management including discharge planning. CONCLUSION: This clinician-led consensus statement establishes the 'best practice' for the management and treatment of AE-IPF based on current knowledge, evidence, and
Cottin V, Maher T, Azuma A, et al., 2015, Pirfenidone Post-Authorization Safety Registry (PASSPORT): Update and Concomitant Use of NAC and/or Corticosteroids, Publisher: AMER COLL CHEST PHYSICIANS, ISSN: 0012-3692
- Author Web Link
- Cite
- Citations: 1
Holman BF, Cuplov V, Millner L, et al., 2015, Improved correction for the tissue fraction effect in lung PET/CT imaging, Physics in Medicine and Biology, Vol: 60, Pages: 7387-7402, ISSN: 1361-6560
Recently, there has been an increased interest in imaging different pulmonary disorders using PET techniques. Previous work has shown, for static PET/CT, that air content in the lung influences reconstructed image values and that it is vital to correct for this 'tissue fraction effect' (TFE). In this paper, we extend this work to include the blood component and also investigate the TFE in dynamic imaging. CT imaging and PET kinetic modelling are used to determine fractional air and blood voxel volumes in six patients with idiopathic pulmonary fibrosis. These values are used to illustrate best and worst case scenarios when interpreting images without correcting for the TFE. In addition, the fractional volumes were used to determine correction factors for the SUV and the kinetic parameters. These were then applied to the patient images. The kinetic parameters K1 and Ki along with the static parameter SUV were all found to be affected by the TFE with both air and blood providing a significant contribution to the errors. Without corrections, errors range from 34-80% in the best case and 29-96% in the worst case. In the patient data, without correcting for the TFE, regions of high density (fibrosis) appeared to have a higher uptake than lower density (normal appearing tissue), however this was reversed after air and blood correction. The proposed correction methods are vital for quantitative and relative accuracy. Without these corrections, images may be misinterpreted.
Kouranos V, Ward S, Kokosi M, et al., 2015, Optimal use of gas transfer values in detecting pulmonary vascular involvement in sarcoidosis, Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
De lauretis A, Visca D, Ward S, et al., 2015, Gastro-oesophageal dismotility measurements in scleroderma-associated interstitial lung disease: Correlation with respiratory and reflux symptoms, Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 1
Sinha A, Bajwah S, Gosker H, et al., 2015, A comparison of two scoring methods for the King's sarcoidosis questionnaire, Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 1
Sinha A, Bajwah S, Gosker H, et al., 2015, A comparison of two scoring methods for the King's brief interstitial lung disease questionnaire, Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
Kreuter M, Wuyts W, Renzoni E, et al., 2015, LATE-BREAKING ABSTRACT: Antiacid therapy and progression free survival in idiopathic pulmonary fibrosis (IPF), Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 1
Molyneaux P, Cookson W, Moffatt M, et al., 2015, LSC Abstract - Changes in the respiratory microbiome during acute exacerbations of Idiopathic Pulmonary Fibrosis, Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
Nolan CM, Canavan JL, Jones SE, et al., 2015, Response of the King's brief interstitial lung disease (KBILD) questionnaire to pulmonary rehabilitation (PR), Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 1
Russell A-M, Sanderson T, Fleming S, et al., 2015, Item generation for a patient reported outcome measure (PRoM) in idiopathic pulmonary fibrosis (IPF): Application of consensus methods, Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
Woodcock H, Peace S, Nanthakumar C, et al., 2015, mTOR signalling is an essential pathway for TGF-β<sub>1</sub> induced collagen synthesis, Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 4
Kreuter M, Wijsenbeek MS, Vasakova M, et al., 2015, LATE-BREAKING ABSTRACT: Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF), Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
Cottin V, Maher TM, Azuma A, et al., 2015, Pirfenidone post-authorization safety registry (PASSPORT) update, Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 2
Maher TM, Flaherty KR, Noble PW, et al., 2015, Effect of baseline FVC on lung function decline with nintedanib in patients with IPF, Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 11
Cottin V, Maher T, 2015, Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis (vol 24, pg 58, 2015), EUROPEAN RESPIRATORY REVIEW, Vol: 24, Pages: 545-545, ISSN: 0905-9180
- Author Web Link
- Cite
- Citations: 4
Spagnolo P, Bonella F, Maher TM, 2015, New guideline on treatment of idiopathic pulmonary fibrosis, LANCET RESPIRATORY MEDICINE, Vol: 3, Pages: E31-E32, ISSN: 2213-2600
- Author Web Link
- Cite
- Citations: 4
Spagnolo P, Tzouvelekis A, Maher TM, 2015, Personalized medicine in idiopathic pulmonary fibrosis: facts and promises, CURRENT OPINION IN PULMONARY MEDICINE, Vol: 21, Pages: 470-478, ISSN: 1070-5287
- Author Web Link
- Cite
- Citations: 37
Patel AS, Siegert RJ, Bajwah S, et al., 2015, Rasch analysis and impact factor methods both yield valid and comparable measures of health status in interstitial lung disease, JOURNAL OF CLINICAL EPIDEMIOLOGY, Vol: 68, Pages: 1019-1027, ISSN: 0895-4356
- Author Web Link
- Cite
- Citations: 9
Spagnolo P, Maher TM, Richeldi L, 2015, Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy, PHARMACOLOGY & THERAPEUTICS, Vol: 152, Pages: 18-27, ISSN: 0163-7258
- Author Web Link
- Cite
- Citations: 60
Maher TM, Piper A, Song Y, et al., 2015, Year in review 2014: Interstitial lung disease, physiology, sleep and ventilation, acute respiratory distress syndrome, cystic fibrosis, bronchiectasis and rare lung disease, RESPIROLOGY, Vol: 20, Pages: 834-845, ISSN: 1323-7799
- Author Web Link
- Cite
- Citations: 2
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.